Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...
Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...
We conducted a single-center, open-label trial in Germany that involved patients with symptomatic atrial fibrillation and end-stage heart failure who were referred for heart transplantation evaluation ...
RF-based ablation is the most common treatment for atrial fibrillation (AFib) — an irregular and usually fast heartbeat. Studies have shown that this procedure is safe and effective, but over the ...
Atrial fibrillation is the most common heart rhythm disorder worldwide and is linked to a higher risk of stroke, heart failure and repeated hospitalizations. Catheter ablation is a widely used ...
Enrollment completed ahead of schedule in the global IDE for Abbott (ABT)'s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Morning Overview on MSN
New catheter aims to improve arrhythmia treatment as clinical trials begin
For the roughly 6 million Americans living with atrial fibrillation, catheter ablation has become an increasingly common ...
EDAP TMS SA announced the positive results of its Focal Ablation Versus Radical Prostatectomy (FARP) Study at the AUA Annual Meeting on April 27, 2025. The trial achieved its primary goal, ...
Cardiac ablation can improve symptoms and may extend a person’s life by treating certain heart arrhythmias. The procedure is often effective, but some serious complications can occur. Cardiac ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results